Abstract P47: Immediate Clinical Improvement Occurs in Patients With Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia Treated With Hypertension Induction or Inotropics

Abstract

Introduction: Delayed cerebral ischemia (DCI) is one of the main determinants of prognosis in aneurysmal subarachnoid hemorrhage (aSAH). Hypertension induction (HI) and inotropics are frequently used strategies to treat DCI. However, little is known about clinical improvement immediately after those therapies. Methods: All patients with aSAH admitted to our hospital from 2016 to 2018 were evaluated. DCI was defined as a new focal neurological deficit or decrease in level of consciousness or the appearance of new infarctions on brain imaging. Patients who developed DCI and received vasopressors or inotropics and were included in the study. They were evaluated before (t0), 45 (t1) and 90 (t2) minutes after therapy initiation using NIHSS scores and Glasgow Coma Scale (GCS). Results: A total of 98 aSAH were evaluated, and 21 of them developed DCI (21.4%). Six patients received both treatment strategies, leading to a total of 27 DCI treatments (norepinephrine =12, milrinone =15). Mean NIHSS score had a significant decrease in t1 and t2 when compared to t0 (17 [95%CI 13-24], 16 [95%CI 11-23], 15 [95%CI 9-22], p<0.001 and p<0.002). The same happened among those treated with IH (t0=18 [95%CI 13-25]; t1=16 [95%CI 11-23], p=0.002; t2=14 [95%CI 9-22], p=0.027) and with milrinone (t0=17 [95%CI 12-24]; t1=15 [95%CI 10-23], p=0.007; t2=14 [95%CI 9-23], p=0.001). Mean GCS had a significant improvement in t1, that was not sustained in t2 (9 [95%CI 8-11], 10 [95%CI 9-12], 10 [95%CI 9-12], p=0.008 and p=0.098). In those treated with HI GCS scores did not change significantly (t0=9 [95%CI 7-11]; t1=10 [95%CI 8-12], p=0.054; t2=10 [95%CI 8-12], p=0.177). Those treated with inotropics significantly improved across time (t0=10 [95%CI 8-12]; t1=11 [95%CI 9-13], p=0.004; t2=11 [95%CI 9-13], p=0.001). Conclusions: DCI treatment with HI or inotropic therapy seems effective in immediately improving neurological deficits in patients with aSAH and DCI.